Author
Listed:
- Feng Wang
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Luyao Zhao
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Yun Tan
(Shanghai Jiao Tong University School of Medicine)
- Xufeng Cen
(Zhejiang University)
- Huan Gao
(Shandong University)
- Huimin Jiang
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Ying Liu
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Yunxuan Li
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Tingting Zhang
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Chenxi Zhao
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
- Ting Shi
(Capital Medical University
Chinese Institutes for Medical Research)
- Guilin Xu
(Shanghai Jiao Tong University School of Medicine)
- Churan Wang
(Shanghai Jiao Tong University School of Medicine)
- Jiong Hu
(Shanghai Jiao Tong University School of Medicine)
- Xia Li
(Shandong University)
- Ya-Zhen Qin
(Peking University People’s Hospital, Peking University Institute of Hematology)
- Kankan Wang
(Shanghai Jiao Tong University School of Medicine)
- Hong-Hu Zhu
(Capital Medical University
Chinese Institutes for Medical Research)
- Ke Li
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Abstract
Acute myeloid leukemia (AML) featuring retinoic acid receptor-gamma (RARG) rearrangements exhibits morphological features resembling those of acute promyelocytic leukemia but is associated with drug resistance and poor clinical outcomes. However, the mechanisms underlying the role of RARG fusions in leukemogenesis remain elusive. Here, we show that RARG fusions disrupt myeloid differentiation and promote proliferation and self-renewal of hematopoietic stem and progenitor cells (HSPCs) by upregulating BCL2 and ATF3. RARG fusions overexpression leads to preleukemic phenotypes but fails to induce oncogenic transformation. However, the co-occurrence of RARG fusions and heterozygous Wt1 loss induce fully penetrant AML by activating MYC and HOXA9/MEIS1 targets. Leveraging Connectivity Map resources and high-throughput screening, we identify venetoclax, homoharringtonine, and daunorubicin as potential therapeutic options for RARG-AML. Overall, our findings provide pivotal insights into the molecular mechanisms governed by RARG fusions and enhanced by WT1 loss in AML development and propose a rational therapeutic strategy for RARG-AML.
Suggested Citation
Feng Wang & Luyao Zhao & Yun Tan & Xufeng Cen & Huan Gao & Huimin Jiang & Ying Liu & Yunxuan Li & Tingting Zhang & Chenxi Zhao & Ting Shi & Guilin Xu & Churan Wang & Jiong Hu & Xia Li & Ya-Zhen Qin & , 2025.
"Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia,"
Nature Communications, Nature, vol. 16(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55047-7
DOI: 10.1038/s41467-024-55047-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55047-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.